- Conditions
- Influenza, Human, Transplantation Infection
- Interventions
- influenza trivalent inactive vaccine, influenza trivalent inactive vaccine high dose
- Biological
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Falls Church, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 835
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections, HIV Seronegativity
- Interventions
- APL 400-003
- Biological
- Lead sponsor
- Wyeth-Lederle Vaccines
- Industry
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HIV
- Interventions
- DV901-NP, DV902-NP, CH505 TF mRNA-gp160, CH505 w24 mRNA-gp160, ACU-026-001-1
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 8
- States / cities
- San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
- Conditions
- Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
- Interventions
- Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 1,167 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2006
- U.S. locations
- 23
- States / cities
- Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 19 more
- Conditions
- Healthy
- Interventions
- Typhoid Vi Polysaccharide Vaccine, Placebo
- Biological
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 30 Years to 60 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- San Francisco, California
- Conditions
- Neisseria Meningitidis
- Interventions
- Trumenba, PENBRAYA
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Influenza
- Interventions
- ASO3 Adjuvant, Influenza A/H5N1 Vaccine
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Staphylococcal Infections, Yeast Infections, Candidiasis
- Interventions
- NDV-3 vaccine with alum IM, NDV-3 vaccine without alum IM, Placebo with alum IM, NDV-3 vaccine without alum ID
- Biological
- Lead sponsor
- NovaDigm Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Pneumococcal Disease
- Interventions
- 31-valent pneumococcal conjugate vaccine, PCV20
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 752 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 30
- States / cities
- Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more
- Conditions
- COVID-19
- Interventions
- AS03, BNT162b2, BNT162b2 (B.1.1.529), BNT162b2 (B.1.351), BNT162b2 bivalent (wildtype and Omicron BA.1), BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5), CoV2 preS dTM [B.1.351], CoV2 preS dTM/D614, CoV2 preS dTM/D614+B.1.351, mRNA-1273, mRNA-1273.351, mRNA-1273.529, mRNA-1273.617.2, Sodium Chloride, 0.9%
- Drug · Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,270 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more
- Conditions
- COVID-19 Prevention
- Interventions
- Ad26.COV2.S, Placebo, Influenza Vaccine
- Biological · Other
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 861 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 17
- States / cities
- Tempe, Arizona • San Diego, California • Coral Gables, Florida + 12 more
- Conditions
- Malaria
- Interventions
- FMP012 with AS01B adjuvant system, P falciparum Controlled Human Malaria Infection (CHMI)
- Biological · Other
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Rabies
- Interventions
- Active rabies vaccine (US-FDA approved)
- Drug
- Lead sponsor
- Kamada, Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- COVID-19 (Healthy Volunteers)
- Interventions
- CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose), CoV2 preS dTM-AS03 (high-dose), CoV2 preS dTM (high-dose) without adjuvant, Placebo (0.9% normal saline)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 441 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more
- Conditions
- HIV Infections, H1N1 Influenza Virus
- Interventions
- Influenza A (H1N1) monovalent vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 39 Years · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 29
- States / cities
- Alhambra, California • La Jolla, California • Long Beach, California + 22 more
- Conditions
- Respiratory Syncytial Viruses, Respiratory Tract Infections
- Interventions
- Ad26.RSV.preF (1*10^11 vp), Ad26.RSV.preF (5*10^10 vp), Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 12 Months to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Newton, Kansas
- Conditions
- Influenza
- Interventions
- Vero cell-derived, trivalent, seasonal influenza vaccine, Placebo: Phosphate-buffered saline
- Biological
- Lead sponsor
- Alachua Government Services, Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 7,250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Sacramento, California • San Diego, California + 31 more
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Interventions
- CYD Dengue Vaccine, Japanese Encephalitis Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- RSV Respiratory Syncytial Virus
- Interventions
- AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 3 more
- Conditions
- Papillomavirus Infections
- Interventions
- 9vHPV Vaccine, Placebo (Saline for Injection)
- Biological · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 20 Years to 45 Years · Male only
- Enrollment
- 6,033 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Northridge, California • Rialto, California • Simi Valley, California + 28 more
- Conditions
- Influenza
- Interventions
- 0.5mL Intramuscular Injection
- Biological
- Lead sponsor
- Protein Sciences Corporation
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 392 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Overland Park, Kansas • Omaha, Nebraska • Rochester, New York + 1 more
- Conditions
- SARS-CoV-2
- Interventions
- Biological: mRNA-1273, Placebo, mRNA-1273.351
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 8
- States / cities
- Savannah, Georgia • Newton, Kansas • Kansas City, Missouri + 5 more
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg, Placebo, Biological/Vaccine: BNT162b2 3mcg
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 6 Months to 15 Years
- Enrollment
- 11,837 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more
- Conditions
- Diphtheria, Tetanus
- Interventions
- Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 11 Years to 60 Years
- Enrollment
- 3,651 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 2
- States / cities
- Oakland, California • Pittsburgh, Pennsylvania